Banco Bilbao Vizcaya Argentaria S.A. Has $6.39 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Banco Bilbao Vizcaya Argentaria S.A. raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 156.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,865 shares of the life sciences company’s stock after buying an additional 29,178 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Illumina were worth $6,393,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ILMN. Bank of Stockton raised its holdings in Illumina by 3.8% in the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after acquiring an additional 80 shares in the last quarter. Stephens Inc. AR increased its position in shares of Illumina by 1.4% during the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after purchasing an additional 90 shares during the period. Spire Wealth Management raised its stake in shares of Illumina by 26.0% in the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock valued at $63,000 after purchasing an additional 97 shares in the last quarter. IFP Advisors Inc lifted its position in Illumina by 19.1% in the fourth quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock worth $82,000 after purchasing an additional 99 shares during the period. Finally, Freedom Investment Management Inc. boosted its stake in Illumina by 3.7% during the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company’s stock worth $382,000 after buying an additional 101 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ILMN. Citigroup dropped their price objective on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a research note on Monday, April 7th. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Morgan Stanley lowered their price objective on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Guggenheim dropped their target price on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and decreased their price target for the company from $177.00 to $140.00 in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Illumina has an average rating of “Moderate Buy” and a consensus price target of $138.70.

Illumina Stock Down 0.3 %

NASDAQ ILMN opened at $77.35 on Friday. The stock has a market capitalization of $12.24 billion, a P/E ratio of -10.07, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The stock has a fifty day moving average of $82.02 and a 200-day moving average of $118.20.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.